Please assess the completion status of the following clinical trial:

Trial Title: D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 18 years.~* Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic.~* Radiological documentation of disease progression while on a previous continuous treatment with an first or second generation of EGFR TKI e.g. gefitinib or erlotinib.~* patients must also have confirmation of tumour T790M mutation status (confirmed positive) after disease progression on the prior EGFR TKI.~* Eastern cooperative oncology group performance status (ECOG PS) of 0-1.~* a minimum life expectancy of 12 weeks.~* At least one lesion, not previously irradiated during the study screening period, that can be accurately measured at baseline according to RECIST 1.1.~* Agree to use routine adequate and effective contraceptive measures during the entire study period and within 6 weeks after the last dose pre-menopausal fertility possible; Female patients need to exclude pregnancy (ie negative pregnancy test) and in non-lactation period.~Exclusion Criteria:~* Treatment with a first or second generation of EGFR-TKI within 10 days of study entry; previous treatment with a third generation of EGFR-TKI.~* Unresolved toxicities from prior therapy.~* Unstable spinal cord compression/brain metastases.~* Severe/uncontrolled systemic diseases, including uncontrolled hypertension, bleeding diatheses or infection.~* QTcF≥470 msec（female）or QTcF≥450 msec（male）during the screening period.~* Severe respiratory diseases such as interstitial lung disease, severe asthma, pulmonary embolism, etc.~* previous treatment with 2 or more lines of Chemotherapy or immunotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- D-0316 (Type: EXPERIMENTAL): Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).